Biomissile
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Biotech company developing first-in-class multi-specific antibodies using proprietary human domain antibody technology for diseases with unmet needs.
OncologyImmunology
Technology Platform
Proprietary UDAB™ (fully human domain antibody) platform for discovering and developing bispecific and multispecific therapeutic antibodies with potential advantages in target engagement and reduced immunogenicity.
Opportunities
Significant opportunity in developing first-in-class multi-specific antibodies for diseases with high unmet medical needs, particularly in oncology and immunology where combination therapies show promise.
Risk Factors
Preclinical stage company with unproven platform technology facing intense competition in the multi-specific antibody space and requiring substantial capital to advance pipeline candidates.
Competitive Landscape
Competes with established players like Amgen, Roche, and emerging Chinese biotechs in multi-specific antibodies; differentiation depends on demonstrating clinical advantages of UDAB™ platform over existing technologies.